These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 33472120)

  • 1. In silico drug repositioning on F508del-CFTR: A proof-of-concept study on the AIFA library.
    Orro A; Uggeri M; Rusnati M; Urbinati C; Pedemonte N; Pesce E; Moscatelli M; Padoan R; Cichero E; Fossa P; D'Ursi P
    Eur J Med Chem; 2021 Mar; 213():113186. PubMed ID: 33472120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virtual Drug Repositioning as a Tool to Identify Natural Small Molecules That Synergize with Lumacaftor in F508del-CFTR Binding and Rescuing.
    Fossa P; Uggeri M; Orro A; Urbinati C; Rondina A; Milanesi M; Pedemonte N; Pesce E; Padoan R; Ford RC; Meng X; Rusnati M; D'Ursi P
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
    Chung WJ; Goeckeler-Fried JL; Havasi V; Chiang A; Rowe SM; Plyler ZE; Hong JS; Mazur M; Piazza GA; Keeton AB; White EL; Rasmussen L; Weissman AM; Denny RA; Brodsky JL; Sorscher EJ
    PLoS One; 2016; 11(10):e0163615. PubMed ID: 27732613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deletion of Phe508 in the first nucleotide-binding domain of the cystic fibrosis transmembrane conductance regulator increases its affinity for the heat shock cognate 70 chaperone.
    Scott-Ward TS; Amaral MD
    FEBS J; 2009 Dec; 276(23):7097-109. PubMed ID: 19878303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological Inhibition of the Ubiquitin Ligase RNF5 Rescues F508del-CFTR in Cystic Fibrosis Airway Epithelia.
    Sondo E; Falchi F; Caci E; Ferrera L; Giacomini E; Pesce E; Tomati V; Mandrup Bertozzi S; Goldoni L; Armirotti A; Ravazzolo R; Cavalli A; Pedemonte N
    Cell Chem Biol; 2018 Jul; 25(7):891-905.e8. PubMed ID: 29754957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Homogeneous Cell-Based Halide-Sensitive Yellow Fluorescence Protein Assay to Identify Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Ion Channel.
    Smith E; Giuliano KA; Shumate J; Baillargeon P; McEwan B; Cullen MD; Miller JP; Drew L; Scampavia L; Spicer TP
    Assay Drug Dev Technol; 2017 Dec; 15(8):395-406. PubMed ID: 29172645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rescuing mutant CFTR: a multi-task approach to a better outcome in treating cystic fibrosis.
    Amaral MD; Farinha CM
    Curr Pharm Des; 2013; 19(19):3497-508. PubMed ID: 23331027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Speeding Up the Identification of Cystic Fibrosis Transmembrane Conductance Regulator-Targeted Drugs: An Approach Based on Bioinformatics Strategies and Surface Plasmon Resonance.
    Rusnati M; Sala D; Orro A; Bugatti A; Trombetti G; Cichero E; Urbinati C; Di Somma M; Millo E; Galietta LJV; Milanesi L; Fossa P; D'Ursi P
    Molecules; 2018 Jan; 23(1):. PubMed ID: 29316712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved correction of F508del-CFTR biogenesis with a folding facilitator and an inhibitor of protein ubiquitination.
    Goeckeler-Fried JL; Aldrin Denny R; Joshi D; Hill C; Larsen MB; Chiang AN; Frizzell RA; Wipf P; Sorscher EJ; Brodsky JL
    Bioorg Med Chem Lett; 2021 Sep; 48():128243. PubMed ID: 34246753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphorylation of the Chaperone-Like HspB5 Rescues Trafficking and Function of F508del-CFTR.
    Degrugillier F; Aissat A; Prulière-Escabasse V; Bizard L; Simonneau B; Decrouy X; Jiang C; Rotin D; Fanen P; Simon S
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32650630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of F508del CFTR unfolding and a search for stabilizing small molecules.
    Meng X; Ford RC
    Arch Biochem Biophys; 2024 Aug; 758():110050. PubMed ID: 38876247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simple image-based no-wash method for quantitative detection of surface expressed CFTR.
    Larsen MB; Hu J; Frizzell RA; Watkins SC
    Methods; 2016 Mar; 96():40-45. PubMed ID: 26361332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Binding screen for cystic fibrosis transmembrane conductance regulator correctors finds new chemical matter and yields insights into cystic fibrosis therapeutic strategy.
    Hall JD; Wang H; Byrnes LJ; Shanker S; Wang K; Efremov IV; Chong PA; Forman-Kay JD; Aulabaugh AE
    Protein Sci; 2016 Feb; 25(2):360-73. PubMed ID: 26444971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-native Conformers of Cystic Fibrosis Transmembrane Conductance Regulator NBD1 Are Recognized by Hsp27 and Conjugated to SUMO-2 for Degradation.
    Gong X; Ahner A; Roldan A; Lukacs GL; Thibodeau PH; Frizzell RA
    J Biol Chem; 2016 Jan; 291(4):2004-2017. PubMed ID: 26627832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a NBD1-binding pharmacological chaperone that corrects the trafficking defect of F508del-CFTR.
    Sampson HM; Robert R; Liao J; Matthes E; Carlile GW; Hanrahan JW; Thomas DY
    Chem Biol; 2011 Feb; 18(2):231-42. PubMed ID: 21338920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new 9-alkyladenine-cyclic methylglyoxal diadduct activates wt- and F508del-cystic fibrosis transmembrane conductance regulator (CFTR) in vitro and in vivo.
    Boucherle B; Bertrand J; Maurin B; Renard BL; Fortuné A; Tremblier B; Becq F; Norez C; Décout JL
    Eur J Med Chem; 2014 Aug; 83():455-65. PubMed ID: 24992073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A chemical corrector modifies the channel function of F508del-CFTR.
    Kim Chiaw P; Wellhauser L; Huan LJ; Ramjeesingh M; Bear CE
    Mol Pharmacol; 2010 Sep; 78(3):411-8. PubMed ID: 20501743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors.
    Amico G; Brandas C; Moran O; Baroni D
    Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31683989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
    Yang H; Ma T
    Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deletion of Phenylalanine 508 in the First Nucleotide-binding Domain of the Cystic Fibrosis Transmembrane Conductance Regulator Increases Conformational Exchange and Inhibits Dimerization.
    Chong PA; Farber PJ; Vernon RM; Hudson RP; Mittermaier AK; Forman-Kay JD
    J Biol Chem; 2015 Sep; 290(38):22862-78. PubMed ID: 26149808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.